Pancreatitis Caused by Mounjaro: Recognising the Signs and Getting Help

You've started Mounjaro and your stomach feels off, here's how to read that

Nausea, loose stools, indigestion and a vague feeling of fullness are among the most commonly reported experiences in the first weeks of Mounjaro treatment. They're well-documented in the clinical data, they tend to arrive after a dose increase, and for most people they settle within days. This is the GI profile of the medicine working as intended (slowing gastric emptying and reducing appetite) not a signal that something has gone wrong.

Pancreatitis feels different. The pancreas sits behind the stomach, and when it becomes inflamed the pain is typically severe, builds over hours rather than minutes, sits in the upper abdomen, and often spreads into the back. It doesn't ease when you shift position. It doesn't pass with a glass of water or a short walk. Vomiting may be present but doesn't relieve the pain. If that description matches what you're experiencing, stop eating and drinking and seek urgent medical help the same day, call 999 or go to A&E. This is not a symptom to phone the pharmacy about first.

A simple habit worth building into your first weeks: once a day, notice whether any stomach discomfort you have is dull and changeable (common GI effects) or constant, worsening and localised to the upper abdomen. That distinction, made consciously, takes under a minute and gives you a useful baseline for spotting a change in character. You can read more about the wider Mounjaro side effects profile to put this in context.

What the MHRA guidance on tirzepatide and pancreatitis actually says

On 29 January 2026, the MHRA issued a Drug Safety Update specifically covering GLP-1 receptor agonist medicines, including tirzepatide. The update confirmed that acute pancreatitis is a known but infrequent risk and reinforced that patients and clinicians should be alert to the symptoms described above. The update did not recommend stopping treatment pre-emptively, it recommended knowing what to look for.

The regulatory picture is consistent across GLP-1 medicines. Pancreatitis appears in the SmPC for Mounjaro as a listed adverse reaction, which is why it is discussed during clinical assessment. Patients with a personal history of pancreatitis, or certain gallbladder conditions that raise the risk, are flagged during prescribing review. This doesn't mean pancreatitis will happen, it means the prescriber considers whether the risk-benefit balance is right for you. For a fuller view of how the risk of pancreatitis with Mounjaro is assessed, the risk of pancreatitis with Mounjaro page covers the evidence in more detail.

If you suspect a side effect from any medicine, the MHRA's Yellow Card scheme lets you report it directly. Reports from patients are taken seriously; they inform ongoing safety monitoring for every medicine on the market.

When to get medical help, and how quickly

Urgent (A&E or 999): severe, persistent upper abdominal pain spreading to the back, not relieved by rest or position change, with or without vomiting. Do not drive yourself. Do not wait to see whether it passes overnight.

Same day (GP or 111): pain that is more than mild but doesn't meet the severe threshold above; yellowing of the skin or whites of the eyes (which can indicate gallbladder involvement, another risk to be aware of on GLP-1 treatment); significant and prolonged vomiting leaving you unable to keep fluids down.

At your next clinical review: any new abdominal symptom that has resolved, however briefly, is worth mentioning. A prescriber can note it in your record, consider whether a dose adjustment makes sense, and update their assessment. The NHS patient information for tirzepatide covers side effects and when to seek medical help in plain language and is worth reading alongside any clinical guidance you receive.

One practical note: if you are on other medicines alongside Mounjaro, your GP should know. Certain drugs and alcohol can independently raise pancreatitis risk, and the full picture matters. If you haven't yet spoken to a clinician about your suitability for this treatment, our free consultation is the place to start that conversation.

How Mounjaro pancreatitis concerns are handled in a supervised treatment pathway

Clinical assessment before prescribing isn't a formality. At nume (sorry, at a service like the one our team runs) a GPhC-registered Independent Prescriber reads your full health history before any prescription is written. Relevant conditions, including previous pancreatitis and gallstones, are specifically considered. That clinical filter is what makes a private prescription route meaningfully safer than obtaining these medicines without proper medical oversight.

Tirzepatide is a Black Triangle medicine, meaning the MHRA requires enhanced post-market monitoring. That's standard for newer medicines, not a cause for alarm, but it does mean that safety data continues to accumulate and guidance is updated as it does. If you want to understand more about whether Mounjaro can cause pancreatitis and how that risk is characterised in practice, the January 2026 Drug Safety Update is one example of that monitoring system working as intended.

If you are already on treatment and have questions about what you've read here, the aftercare team is available seven days a week. If you want to read more about how pancreatitis and Mounjaro interact in practice, our page looking at whether Mounjaro can cause pancreatitis addresses the question directly alongside the Mounjaro and pancreatitis page, which goes further into the clinical background. For broader context on this treatment, the Mounjaro overview covers how it works, who it's suitable for, and what the evidence shows.